Latamed eye drops solution 2.5 ml. №1 vial


Manufacturer: Romania

Reduction of intraocular pressure in patients with open-angle glaucoma and increased intraocular pressure, with insufficient response to treatment with beta-blockers or local prostaglandin analogues.



Latamed Storage
active substances: latanoprost, timolol;

1 ml of solution contains latanoprost 0.05 mg, timolol (in the form of maleate) 5 mg;

Excipients: disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, benzalkonium chloride, sodium hydroxide or hydrochloric acid, purified water.

Latamed Dosage form
Eye drops, solution.

Basic physical and chemical properties: transparent colorless solution.

Latamed Pharmacotherapeutic group
Antiglaucoma drugs and miotics. Beta-blocking agents. Timolol, combinations. Code ATX S01E D51.

Pharmacological properties

Latamed Mechanism of action.

The drug contains two active substances: latanoprost and timolol. Both components reduce elevated intraocular pressure by different mechanisms of action, the combined effect leads to a more pronounced decrease in intraocular pressure compared to monotherapy with each of them.

Latanoprost, an analogue of prostaglandin F2α, is a selective agonist of the prostanoid receptor FP, which reduces intraocular pressure by increasing the outflow of aqueous humor. The main mechanism of action is to increase uveoscleral outflow. In addition, slightly increased outflow (decreased resistance to outflow in the trabeculae) has been reported in humans. Latanoprost does not significantly affect the production of aqueous humor and the blood-brain barrier or intraocular blood circulation. Prolonged use of latanoprost in monkeys who underwent extracapsular lens extraction did not affect the retinal vessels, according to fluorescent angiography. Latanoprost did not induce fluorescein leakage in the posterior segment of the eye in patients with pseudophakia for a short course of treatment.

Decreased intraocular pressure in patients with open-angle glaucoma and increased intraocular pressure with insufficient response to treatment with topical beta-blockers or prostaglandin analogues.

Hypersensitivity to the active substances and / or to other excipients of the medicinal product.
Reactive diseases of the respiratory tract, including a history of bronchial asthma or bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia; sinus weakness syndrome; sinoauricular block; atrioventricular block of the II or III degree which is not subject to control by means of the rhythm driver; clinically pronounced heart failure; cardiogenic shock.
Interaction with other medicinal products and other forms of interaction
No special studies have been performed on the interaction of latanoprost / timolol with other drugs.

Prostaglandins, prostaglandin analogues or prostaglandin derivatives.

A paradoxical increase in intraocular pressure has been reported after concomitant use of two prostaglandin analogs. Therefore, the use of two or more prostaglandins, prostaglandin analogues or prostaglandin derivatives is not recommended.

Oral calcium channel blockers, antiarrhythmics (including amiodarone), foxglove glycosides, parasympathomimetics, guanethidine.